Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients With Mild to Moderate Alzheimer's Disease Treated With a Cholinesterase Inhibitor

NCT00277810 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00277810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00277810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients With Mild to Moderate Alzheimer's Disease Treated With a Cholinesterase Inhibitor
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2006
Completion date
June 30, 2008
Enrollment
250 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease